UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~FORM~~ Form 8-K

CURRENT REPORT

~~Pursuant~~PURSUANT TO toSECTION ~~Section~~ 13 orOR 15(dD) ofOF ~~the Securities Exchange Act of 1934~~THE

~~Date~~SECURITIES EXCHANGE ofACT ~~Report~~OF ~~(Date of earliest event reported): August 7, 2009~~1934

Date of Report (Date of earliest event reported): August 11, 2009

WEIKANG BIO-TECHNOLOGY GROUP COMPANY, INC.

(Exact name ~~Name~~ of ~~Registrant~~registrant as ~~Specified~~specified in ~~Charter~~its charter)

Nevada		000-1365354		26-2816569
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Nevada

(State or other

jurisdiction of incorporation)

000-1365354

(Commission

File Number)

26-2816569

(I.R.S. Employer

Identification No.)

No. 365 Chengde Street, Daowai District, Harbin

Heilongjiang Province, ~~PRC~~The People’s Republic of China 150020

(Address of principal executive offices) ~~and~~ (zip code)

~~Registrant’s telephone number, including area code:~~ (86) 0451-88355530

(Registrant’s telephone number, including area code)

Not Applicable .

(Former name or former address, if changed since last report.)

Copies to:

Benjamin A. Tan, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32nd Floor,

New York, NY 10006

Tel: (212) 930 9700

Fax: (212) 930 9725

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 ~~DFR~~ CFR 240.14a-12)

 o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 ¨ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

~~WEIKANG~~ Item 1.01. Entry ~~BIO-TECHNOLOGY~~into ~~GROUP~~a ~~COMPANY,~~Material ~~INC.~~Definitive Agreement

~~CURRENT~~Item ~~REPORT~~3.02 ONUnregistered ~~FORM~~Sales ~~8-K~~of Equity Securities

~~TABLE~~Item 3.03. Material Modification OFto ~~CONTENTS~~Rights of Security Holders

~~Item~~Series ~~8.01~~A ~~Other~~Preferred ~~Events~~Stock Securities ~~Item~~Purchase ~~9.01 Financial Statements and Exhibits Exhibit – 10.1 Approval Letter Signatures~~Agreement

~~Item~~On 8August 11, 2009, Weikang Bio-Technology Group Company, Inc.~~01 Other~~ ~~Events~~(the "Company") entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with ARC China, Inc., a Shanghai corporation ("ARC").

OnPursuant to ~~October~~the ~~25,~~terms ~~2007,~~of ~~Sinary Bio-Technology~~the ~~Holdings~~Securities ~~Group~~Purchase Agreement, ~~Inc.~~ARC ~~(“Sinary”)~~agreed ~~entered~~that ~~into~~it anwill purchase ~~equity~~up ~~interests~~to ~~transfer~~an ~~agreement~~aggregate ~~(the “Transfer Agreement”) with the owners~~ of ~~Heilongjiang Weikang Bio-Technology Group Co.~~4,768,877 ~~Ltd.~~Units ~~(“Weikang”),~~at a ~~limited~~purchase ~~liability~~price ~~company~~of in$1.75 ~~the~~per Unit ~~People's~~for ~~Republic~~an ofaggregate ~~China~~purchase ~~(“PRC”~~price orof ~~“China”)~~$8,345,535. Each to"Unit" consists ~~acquire 100%~~ of ~~the~~(i) ~~equity~~one ~~interests~~share of ~~Weikang for~~ the ~~sum~~Company's ofnewly-designated 57Series ~~million~~A ~~Renminbi (“RMB”)~~preferred stock, orpar ~~approximately~~value 7$0.601 ~~million~~per ~~dollars~~share (~~the~~"Series ~~“Acquisition~~A ~~Price”~~Preferred Stock")~~. In connection therewith~~, onand ~~November 6, 2007, Weikang was approved by the Heilongjiang Provincial Government as a foreign invested enterprise~~ (~~“FIE”~~ii), one-half ~~and~~warrant ~~the acquisition of Weikang was deemed completed on November 9, 2007~~ (~~the “Issuance Date”~~"Warrant"), ~~upon~~to ~~the~~purchase one ~~issuance~~share ~~by the Heilongjiang Office~~ of the ~~State~~Company's ~~Administration~~common ~~for Industry and Commerce of a business license to Weikang as a FIE~~stock, ~~with~~par ~~Sinary~~value ~~as the registered owner of 100% of Weikang’s registered capital~~$0. ~~Pursuant~~00001 toper ~~the~~share ~~terms~~("Common ~~of the Transfer Agreement and the requirements of applicable PRC laws and regulations~~Stock"), ~~Sinary~~at ~~had~~ a ~~grace~~price of ~~period~~$2.75 ~~until~~per ~~August 6~~share, ~~2009~~pursuant to ~~remit~~one ~~the~~or ~~Acquisition Price~~more ~~(please~~closings ~~see~~on ~~the~~such ~~risk~~dates ~~factors concerning the acquisition of Weikang under the sections titled “Risks Related to Our Corporate Structure”~~ and ~~“Risks Related to an Investment~~ in ~~Our~~such amounts ~~Securities”~~as indetermined ~~the~~by ~~Risk~~ARC ~~Factor~~upon ~~section~~three ofdays ~~our~~notice ~~Annual~~provided ~~Report~~to ~~on Form 10K filed with~~ the ~~Securities~~Company ~~Exchange Commission on April 15, 2009 at pages 12 and 14). After~~ (the ~~Closing of the Share Exchange Transaction on December~~ 7,"Series ~~2007,~~A ~~Sinary became a wholly-owned subsidiary of Expedition Leasing~~Purchase Transaction"). ~~Other than all of the registered equity interests of Weikang, Sinary has no other assets or operations.~~

InSubject to ~~accordance~~the ~~with~~satisfaction ~~the~~or ~~terms~~waiver of the ~~Transfer~~conditions ~~Agreement,~~set ~~Weikang~~forth ~~has~~in ~~applied~~Section ~~for~~2.2 ~~and~~of ~~received~~the Securities ~~PRC~~Purchase ~~government~~Agreement, ~~approval~~ARC ~~for~~expects anto ~~extension~~close on ~~the~~up ~~remittance~~to ~~date~~$1,000,000 ofin ~~the~~Units on ~~Acquisition~~or ~~Price. Sinary~~about ~~received~~August ~~PRC~~15, ~~government~~2009, ~~approval~~and onadditional ~~August~~Units 7,up ~~2009~~to ~~for~~ an ~~extension~~aggregate of 4,768,877 ~~the~~Units ~~remittance~~on ~~date~~or ~~until~~before ~~June~~August 3031, ~~2010.~~2009, ~~A translation~~but ofno ~~the~~later ~~approval~~than ~~letter~~September ~~is attached as Exhibit 10~~15, 2009.~~1 hereto.~~

~~Item~~The Company 9agreed that an aggregate of $100,000 of the purchase price of the Units will be retained by an escrow agent from the proceeds received in a second closing (the "IR Cash"), which along with an aggregate of 700,000 Warrants (the "IR Warrants") may be allocated and released to investor relations firms for marketing purposes at the sole discretion of ARC.~~01 Financial~~ ~~Statements~~In addition, ARC agreed that it will escrow 3% of the Series A Preferred Stock purchased by it (the "IR Shares"), which will released to investor relations firms at the sole discretion of ARC. Upon the receipt of written instructions executed by ARC, the escrow agent will release all or any portion of the IR Cash, the IR Warrants or the IR Shares as designated by ARC in its sole discretion. If any portion of the IR Cash, IR Warrants or IR Shares remain in the escrow account after a period of 12 months from the date of this Agreement, such IR Cash or IR Warrants, if any, shall be released to the Company, and ~~Exhibits~~such IR Shares, if any, shall be released to ARC, upon receipt of written request from the Company or ARC, as applicable.

The Company expects that the issuance of shares of Series A Preferred Stock and the Warrants pursuant to the terms of the Securities Purchase Agreement will be exempt from registration under Section 4(d2) ~~Exhibits~~of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder, based upon the Company's compliance with such rules and regulations.

~~The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.~~Warrant

~~Exhibit~~Each warrant has an exercise price of $2.75 and is exercisable for a period of three years from the date of issuance. The warrant may be exercised by the payment of cash or by "cashless exercise."

~~Exhibit~~If, –at any ~~10.1~~time ~~Approval~~or ~~Letter~~from time to time after the date of issuance of the warrant, the Company were to issue any additional stock without consideration or for consideration per share less than the exercise price of the warrant, such exercise price shall be adjusted to the price per share at which such additional stock was issued (or if such additional stock was issued for no consideration the price shall be adjusted to $.01).

~~SIGNATURES~~Registration Rights Agreement

~~Pursuant~~In connection with the Series A Purchase Transaction, the Company entered into a Registration Rights Agreement with ARC dated August 11, 2009 (the "Registration Rights Agreement"), pursuant to which the ~~requirements~~Company ofagreed to use its commercially reasonable efforts to cause a registration statement on Form S-3 (or such other form as is available to the Company) to be filed with the Securities and Exchange ~~Act~~Commission (the "SEC") within 30 calendar days of ~~1934,~~the final closing of the ~~Registrant~~sale ~~has~~of ~~duly~~Units ~~caused~~in ~~this~~the ~~report~~Series toA bePurchase Transaction ~~signed~~(“Trigger Date”), onwhich ~~its~~registration ~~behalf~~statement bywill include the ~~undersigned~~Common ~~thereunto~~Stock issuable ~~duly~~upon ~~authorized~~the conversion of the Series A Preferred Stock and upon the exercise of the Warrants.

~~Date:~~In ~~August~~the 11event the SEC informs the Company that all of the registrable securities cannot, ~~2009 Weikang~~as a result of the ~~Bio-Technology~~application ~~Group~~of Rule 415 under the Securities Act of 1933, as amended (the "Securities Act"), be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly (i) inform each of the holders thereof, ~~Inc~~(ii) use its best efforts to file amendments to the registration statement as required by the SEC, or (iii) withdraw the initial registration statement and file a new registration statement, covering the maximum number of securities permitted to be registered by the SEC.

Thereafter, ~~/s/~~the ~~Yin~~Company ~~Wang~~will use its commercially reasonable efforts to file with the SEC, as promptly as allowed by the SEC, one or more registration statements on Form S-3 or such other form available to register for resale those securities that were not registered for resale on the earlier registration statement.

~~Yin~~The Company ~~Wang~~shall use its commercially reasonable efforts to cause the registration statement to become effective no later than the earlier of 90 calendar days after the Trigger Date (or, in the event of a "full review" of the Registration Statement by the SEC, 150 calendar days after the Trigger Date) or five days after the SEC declares the Registration Statement effective. If the registration statement has not been filed or declared effective as aforesaid, the Company shall be liable for late registration payments, equal to one percent of the purchase price paid for the Series A Preferred Stock purchased and not previously sold until the Registration Statement is filed or declared effective, as the case may be. However, such late registration payment shall not exceed in the aggregate 10% of the price.

~~Chief~~The foregoing ~~Executive~~descriptions ~~Officer~~of the Securities Purchase Agreement, the Registration Rights Agreement and the Warrants are qualified in their entirety by the contents of the Securities Purchase Agreement, the Registration Rights Agreement and the Warrants attached as Exhibit 10.1, 10.2 and 4.1, respectively, to this Current Report on Form 8-K.

~~Chairman~~Item 9.01. ofFinancial ~~the~~Statements ~~Board~~and Exhibits.

(d)		Exhibits

		4.1 Form of Warrant
		10.1 Securities Purchase Agreement dated August 11, 2009 between the Company and ARC China, Inc.

		10.2 Registration Rights Agreement between the Company and ARC, Inc. dated August 11, 2009.

The information in this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and shall not be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filings, except as shall be expressly set forth by specific reference in such a filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 17, 2009	WEIKANG BIO-TECHNOLOGY GROUP COMPANY, INC.

	By: /s/ Yin Wang
	Yin Wang
	Chief Executive Officer and Chairman of the Board

Filing Compare · WEIKANG BIO-TECH